4//SEC Filing
Zynerba Pharmaceuticals, Inc. 4
Accession 0001123292-16-002600
CIK 0001621443operating
Filed
Aug 16, 8:00 PM ET
Accepted
Aug 17, 2:19 PM ET
Size
7.6 KB
Accession
0001123292-16-002600
Insider Transaction Report
Form 4
Hanlon Suzanne M.
General Counsel
Transactions
- Sale
Common Stock
2016-08-16$10.53/sh−3,000$31,590→ 0 total(indirect: By Spouse) - Purchase
Common Stock
2015-08-05$17.92/sh+3,000$53,760→ 3,000 total(indirect: By Spouse)
Holdings
- 39,893
Common Stock
Footnotes (2)
- [F1]The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.47 to $10.70, inclusive. The reporting person undertakes to provide Zynerba Pharmaceuticals, Inc., any security holder of Zynerba Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
Documents
Issuer
Zynerba Pharmaceuticals, Inc.
CIK 0001621443
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001621443
Filing Metadata
- Form type
- 4
- Filed
- Aug 16, 8:00 PM ET
- Accepted
- Aug 17, 2:19 PM ET
- Size
- 7.6 KB